Surgical Decision Making in Genetically High-Risk Women: Quantifying Postoperative Complications and Long-Term Risks of Supplemental Surgery After Risk-Reducing Mastectomy.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 03 07 2023
accepted: 25 09 2023
medline: 7 12 2023
pubmed: 15 10 2023
entrez: 14 10 2023
Statut: ppublish

Résumé

Risk-reducing mastectomy (RRM) helps prevent breast cancer in high-risk women but also carries a risk of unanticipated supplemental surgeries. We sought to determine the likelihood of supplemental surgeries following RRM. We performed a retrospective cohort study of female patients with a confirmed germline pathogenic variant (GPV) in a breast cancer susceptibility gene (BRCA1/2, PALB2 and others) who underwent bilateral or contralateral RRM at our institution between 2006 and 2022. Supplemental surgeries were defined as any operation requiring general or local anesthesia performed outside of the initially planned procedure(s). The Kaplan-Meier method was used to estimate the 5-years cumulative incidence of supplemental surgery. Of 560 GPV carriers, RRMs were performed in 258 (46.1%) women. The median age of the cohort was 44 years (interquartile range 37-52 years), with 33 (12.8%) patients undergoing RRM without reconstruction and 225 (87.2%) undergoing RRM with reconstruction. Following surgery, 34 patients (13.2%) developed early (< 30 days) postoperative complications, including infection, hematoma, seroma, loss of the nipple areola complex, flap necrosis, implant exposure and/or prosthesis removal. At a median follow-up of 3.8 years, 94 (36.4%) GPV carriers underwent at least one reoperation. Participants who experienced an early postoperative complication had the highest rate of reoperation (85.3% vs. 29.0%; p < 0.001) and a significantly higher likelihood of multiple additional surgical interventions (41.2% vs. 10.7%; p < 0.001). The 5-years rate of supplemental surgery was 39.2% [95% confidence interval (CI) 32.7-46.5] in the overall cohort and 31.5% (95% CI 24.9-39.3) in patients without an early postoperative complication. Unanticipated supplemental surgeries occur in 40% of GPV carriers following RRM and in nearly one-third of patients without early postoperative complications.

Sections du résumé

BACKGROUND BACKGROUND
Risk-reducing mastectomy (RRM) helps prevent breast cancer in high-risk women but also carries a risk of unanticipated supplemental surgeries. We sought to determine the likelihood of supplemental surgeries following RRM.
METHODS METHODS
We performed a retrospective cohort study of female patients with a confirmed germline pathogenic variant (GPV) in a breast cancer susceptibility gene (BRCA1/2, PALB2 and others) who underwent bilateral or contralateral RRM at our institution between 2006 and 2022. Supplemental surgeries were defined as any operation requiring general or local anesthesia performed outside of the initially planned procedure(s). The Kaplan-Meier method was used to estimate the 5-years cumulative incidence of supplemental surgery.
RESULTS RESULTS
Of 560 GPV carriers, RRMs were performed in 258 (46.1%) women. The median age of the cohort was 44 years (interquartile range 37-52 years), with 33 (12.8%) patients undergoing RRM without reconstruction and 225 (87.2%) undergoing RRM with reconstruction. Following surgery, 34 patients (13.2%) developed early (< 30 days) postoperative complications, including infection, hematoma, seroma, loss of the nipple areola complex, flap necrosis, implant exposure and/or prosthesis removal. At a median follow-up of 3.8 years, 94 (36.4%) GPV carriers underwent at least one reoperation. Participants who experienced an early postoperative complication had the highest rate of reoperation (85.3% vs. 29.0%; p < 0.001) and a significantly higher likelihood of multiple additional surgical interventions (41.2% vs. 10.7%; p < 0.001). The 5-years rate of supplemental surgery was 39.2% [95% confidence interval (CI) 32.7-46.5] in the overall cohort and 31.5% (95% CI 24.9-39.3) in patients without an early postoperative complication.
CONCLUSIONS CONCLUSIONS
Unanticipated supplemental surgeries occur in 40% of GPV carriers following RRM and in nearly one-third of patients without early postoperative complications.

Identifiants

pubmed: 37838650
doi: 10.1245/s10434-023-14418-y
pii: 10.1245/s10434-023-14418-y
doi:

Substances chimiques

BRCA1 protein, human 0
BRCA1 Protein 0
BRCA2 protein, human 0
BRCA2 Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-364

Subventions

Organisme : Fonds de Recherche du Québec - Santé
ID : 309854

Informations de copyright

© 2023. Society of Surgical Oncology.

Références

Rolnick SJ, Altschuler A, Nekhlyudov L, et al. What women wish they knew before prophylactic mastectomy. Cancer Nurs. 2007;30(4):285–91.
doi: 10.1097/01.NCC.0000281733.40856.c4 pubmed: 17666977
St-Pierre D, Bouchard K, Gauthier L, et al. Perspectives of women considering bilateral prophylactic mastectomy and their peers towards a telephone-based peer support intervention. J Genet Couns. 2018;27(1):274–88.
doi: 10.1007/s10897-017-0148-x pubmed: 28916957
Moberg IO, Schou Bredal I, Schneider MR, et al. Complications, risk factors, and patients-reported outcomes after skin-sparing mastectomy followed by breast reconstruction in women with BRCA mutations. J Plast Surg Hand Surg. 2018;52(4):234–9.
doi: 10.1080/2000656X.2018.1470093 pubmed: 29741462
Zion SM, Slezak JM, Sellers TA, et al. Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer. 2003;98(10):2152–60.
doi: 10.1002/cncr.11757 pubmed: 14601084
Nurudeen S, Guo H, Chun Y, et al. Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers. Am J Surg. 2017;214(4):687–94.
doi: 10.1016/j.amjsurg.2017.06.017 pubmed: 28683895
Cohen WA, Ballard TN, Hamill JB, et al. Understanding and optimizing the patient experience in breast reconstruction. Ann Plast Surg. 2016;77(2):237–41.
doi: 10.1097/SAP.0000000000000550 pubmed: 26101986 pmcid: 4685029
Metcalfe K, Eisen A, Senter L, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15–21.
doi: 10.1038/s41416-019-0446-1 pubmed: 30971774 pmcid: 6738089
Roberts A, Baxter NN, Sutradhar R, et al. Reoperation cascade in postmastectomy breast reconstruction and its associated factors: results from a long-term population-based study. J Surg Oncol. 2020;122(7):1300–6.
doi: 10.1002/jso.26166 pubmed: 32964476
Fischer JP, Fox JP, Nelson JA, et al. A longitudinal assessment of outcomes and healthcare resource utilization after immediate breast reconstruction-comparing implant- and autologous-based breast reconstruction. Ann Surg. 2015;262(4):692–9.
doi: 10.1097/SLA.0000000000001457 pubmed: 26366550
King CA, Bartholomew AJ, Sosin M, et al. A critical appraisal of late complications of prepectoral versus subpectoral breast reconstruction following nipple-sparing mastectomy. Ann Surg Oncol. 2021;28(13):9150–8.
doi: 10.1245/s10434-021-10085-z pubmed: 34386913
Sobti N, Weitzman RE, Nealon KP, et al. Evaluation of capsular contracture following immediate prepectoral versus subpectoral direct-to-implant breast reconstruction. Sci Rep. 2020;10(1):1137.
doi: 10.1038/s41598-020-58094-4 pubmed: 31980737 pmcid: 6981172
Patel AA, Cemaj SL, Martin SA, et al. Revision rates in prepectoral versus subpectoral delayed-immediate autologous breast reconstruction. Ann Plast Surg. 2021;86(5S Suppl 3):S409–13.
doi: 10.1097/SAP.0000000000002760 pubmed: 33833169
de Blacam C, Ogunleye AA, Momoh AO, et al. High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national surgical quality improvement program database. Ann Surg. 2012;255(3):551–5.
doi: 10.1097/SLA.0b013e318246c294 pubmed: 22330036
Arver B, Isaksson K, Atterhem H, et al. Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Ann Surg. 2011;253(6):1147–54.
doi: 10.1097/SLA.0b013e318214b55a pubmed: 21587115
Unukovych D, Sandelin K, Wickman M, et al. Breast reconstruction in patients with personal and family history of breast cancer undergoing contralateral prophylactic mastectomy, a 10-year experience. Acta Oncol. 2012;51(7):934–41.
doi: 10.3109/0284186X.2012.666000 pubmed: 22409595
Berry T, Brooks S, Sydow N, et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction. Ann Surg Oncol. 2010;17(Suppl 3):202–10.
doi: 10.1245/s10434-010-1261-3 pubmed: 20853034
Eom JS, Kobayashi MR, Paydar K, et al. The number of operations required for completing breast reconstruction. Plast Reconstr Surg Glob Open. 2014;2(10):e242.
doi: 10.1097/GOX.0000000000000111 pubmed: 25426359 pmcid: 4236387
Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000;284(3):319–24.
doi: 10.1001/jama.284.3.319 pubmed: 10891963
Klapdor R, Weiss C, Kuehnle E, et al. Quality of Life after Bilateral and Contralateral Prophylactic Mastectomy with Implant Reconstruction. Breast Care (Basel). 2020;15(5):519–26.
doi: 10.1159/000505449 pubmed: 33223996
Ho AL, Klassen AF, Cano S, et al. Optimizing patient-centered care in breast reconstruction: the importance of preoperative information and patient-physician communication. Plast Reconstr Surg. 2013;132(2):212e–20e.
doi: 10.1097/PRS.0b013e31829586fa pubmed: 23897349
D’Alonzo M, Piva E, Pecchio S, et al. Satisfaction and impact on quality of life of clinical and instrumental surveillance and prophylactic surgery in BRCA-mutation carriers. Clin Breast Cancer. 2018;18(6):e1361–6.
doi: 10.1016/j.clbc.2018.07.015 pubmed: 30122348

Auteurs

Carla Apostolova (C)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Stroll Cancer Prevention Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.

Amina Ferroum (A)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Stroll Cancer Prevention Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.

Basmah Alhassan (B)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Department of Oncology, McGill University Medical School, Montreal, QC, Canada.

Ipshita Prakash (I)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Stroll Cancer Prevention Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Department of Oncology, McGill University Medical School, Montreal, QC, Canada.

Alex Viezel-Mathieu (A)

Department of Plastic and Reconstructive Surgery, McGill University Medical School, Montreal, QC, Canada.

Mark Basik (M)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Department of Oncology, McGill University Medical School, Montreal, QC, Canada.

Jean Francois Boileau (JF)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.

Sarkis Meterissian (S)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.
Department of Oncology, McGill University Medical School, Montreal, QC, Canada.

Nora Wong (N)

Stroll Cancer Prevention Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Department of Human Genetics, McGill University Medical School, Montreal, QC, Canada.

William D Foulkes (WD)

Stroll Cancer Prevention Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Department of Oncology, McGill University Medical School, Montreal, QC, Canada.
Department of Human Genetics, McGill University Medical School, Montreal, QC, Canada.

Stephanie M Wong (SM)

Department of Surgery, McGill University Medical School, Montreal, QC, Canada. sm.wong@mcgill.ca.
Stroll Cancer Prevention Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada. sm.wong@mcgill.ca.
Department of Oncology, McGill University Medical School, Montreal, QC, Canada. sm.wong@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH